From: Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer
Variant | HR for PFS | 95% CI | p |
---|---|---|---|
Baseline TSH level | 0.983 | 0.834–1.159 | 0.840 |
Time of occurrence of TD (month) | 0.944 | 0.876–1.018 | 0.137 |
Severity of TD | 1.284 | 0.439–3.754 | 0.648 |
Regression of TD | 0.816 | 0.384–1.733 | 0.597 |
Time of reversion (month) | 1.010 | 0.637–1.601 | 0.577 |
Duration of TD (month) | 0.907 | 0.844–0.975 | 0.008 |